Cabozantinib and thromboembolism in patients with cancer: a systematic review, meta-analysis, and retrospective study.

However, concerns have arisen over potential associations between antiangiogenic agents and thromboembolic events.

然而，人们开始关注抗血管生成剂与血栓栓塞事件之间可能存在的关联。

We performed a systematic reviewand meta-analysisof randomized controlled trials (RCTs) that compared a frequently used VEGFR TKI, cabozantinib, with placebo or usual care.

我们进行了一项系统综述和荟萃分析，比较了常用的VEGFR酪氨酸激酶抑制剂卡博替尼与安慰剂或常规治疗的随机对照试验(RCTs)。

The primary outcome was the risk of any thromboembolism.

主要结果是任何血栓栓塞事件的风险。

Secondary outcomes included the risk of venous thromboembolism (VTE), risk of arterial thromboembolism (ATE) and progression-free survival. 14 RCTs were included with a combined total of 4204 patients, of whom 212 (5%) developed thromboembolism.

次要结果包括静脉血栓栓塞(VTE)的风险、动脉血栓栓塞(ATE)的风险以及无进展生存期。共纳入了14项随机对照试验(RCTs)，总共有4204名患者，其中212名（5%）发生了血栓栓塞。

Cabozantinib was associated with a significantly increased risk of any thromboembolism (risk ratio [RR], 2.41; 95% confidence interval[CI], 1.72-3.39) driven by VTE (RR, 3.21; 95% CI, 1.86-5.55) but not ATE (RR, 1.31; 95% CI, 0.76-2.26).

Cabozantinib与任何血栓栓塞的显著增加风险相关（风险比[RR]，2.41；95%置信区间[CI]，1.72-3.39），这主要由VTE驱动（RR，3.21；95% CI，1.86-5.55），但与ATE无关（RR，1.31；95% CI，0.76-2.26）。

To account for between-group differences in time on treatment, progression-free survival-adjusted analyses were conducted, with cabozantinib remaining associated with a significantly increased risk of any thromboembolism (RR, 1.47; 95% CI, 1.02-2.12) and VTE (RR, 1.92; 95% CI, 1.08-3.43) but not ATE (RR, 0.76; 95% CI, 0.41-1.40).

为了校正治疗时间上的组间差异，进行了无进展生存期调整分析，结果显示卡博替尼与任何血栓栓塞事件（RR, 1.47; 95% CI, 1.02-2.12）和静脉血栓栓塞（VTE）（RR, 1.92; 95% CI, 1.08-3.43）的风险显著增加有关，但与动脉血栓栓塞（ATE）无关（RR, 0.76; 95% CI, 0.41-1.40）。

In a retrospective single health care system cohort study of 295 patients treated with cabozantinib, a thromboembolism rate of 180 per 1000 patient-years on treatment was observed, with most events occurring in the first 3 months after initiation.

在一项回顾性单个医疗保健系统队列研究中，对295名接受卡博替尼治疗的患者进行了观察，治疗期间每1000患者年血栓栓塞事件发生率为180例，大多数事件发生在治疗开始后的前3个月内。

Together these data demonstrate that cabozantinib is associated with a significantly increased risk of VTE in patients with cancer.

这些数据共同表明，卡博替尼与癌症患者发生静脉血栓栓塞（VTE）的风险显著增加。